Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPDZ.L Regulatory News (PDZ)

  • There is currently no data for PDZ

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Appendix 3B - Issue of Performance Rights

7 Feb 2018 07:00

RNS Number : 1463E
Prairie Mining Limited
07 February 2018
 

PRAIRIE MINING LIMITED

NEWS RELEASE | 7 February 2018

Appendix 3B - Issue of Performance Rights

Prairie Mining Limited (Company) announces that 1,500,000 unlisted Performance Rights have been issued today to keys employees and consultants of the Company pursuant to the Company's long-term incentive Performance Rights Plan.

No new Ordinary Shares are being issued.

 

The below figure of 167,498,969 Ordinary Shares can be continued to be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company, under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Prairie Mining Limited

 

Ben Stoikovich, Chief Executive Officer

Tel: +44 207 478 3900

Sapan Ghai, Head of Corporate Development

Email: info@pdz.com.au

 

 

 

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

 

New issue announcement,

application for quotation of additional securities

and agreement

 

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

 

Name of entity

PRAIRIE MINING LIMITED

 

ABN

23 008 677 852

 

We (the entity) give ASX the following information.

 

Part 1 ‑ All issues

You must complete the relevant sections (attach sheets if there is not enough space).

 

1

+Class of +securities issued or to be issued

Performance share rights

 

 

 

 

 

2

Number of +securities issued or to be issued (if known) or maximum number which may be issued

1,500,000

 

 

 

 

 

 

3

Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

Performance share rights which do not have an exercise price but are subject to various performance conditions (including: Jan Karski Construction; Debiensko Feasibility Study; and Debiensko Construction Milestones) to be satisfied prior to the relevant expiry dates between 31 December 2018 and 31 December 2020

 

 

 

 

 

4

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

 

If the additional +securities do not rank equally, please state:

· the date from which they do

· the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

· the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

No - not listed

 

 

 

 

 

 

5

Issue price or consideration

 

Nil - see below

 

 

 

 

 

 

 

6

Purpose of the issue

(If issued as consideration for the acquisition of assets, clearly identify those assets)

 

 

 

 

 

 

Issue of performance share rights to key employees and consultants of the Company

 

 

 

 

 

 

 

6a

Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?

 

If Yes, complete sections 6b - 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

No

 

 

 

 

 

 

6b

The date the security holder resolution under rule 7.1A was passed

Not applicable

 

 

 

 

 

 

 

6c

Number of +securities issued without security holder approval under rule 7.1

Not applicable

 

 

 

 

 

 

 

6d

Number of +securities issued with security holder approval under rule 7.1A

Not applicable

 

 

 

 

 

 

 

6e

Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)

 

Not applicable

 

 

 

 

 

 

 

6f

Number of +securities issued under an exception in rule 7.2

Not applicable

 

 

 

 

 

 

 

6g

If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.

Not applicable

 

 

 

 

 

 

6h

If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements

Not applicable

 

 

 

 

 

 

6i

Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A - complete Annexure 1 and release to ASX Market Announcements

Rule 7.1 - 24,486,845

Rule 7.1A - Not applicable

 

 

 

 

 

7

+Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

7 February 2018

 

 

 

 

 

Number

+Class

8

Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)

 

 

 

167,498,969

Ordinary Shares

 

 

 

Number

+Class

9

Number and +class of all +securities not quoted on ASX (including the +securities in section 2 if applicable)

 

 

 

1,400,000

 

 

200,000

 

 

 

900,000

 

 

 

700,000

 

 

 

10,925,000

 

 

 

 

 

 

 

44,776,120

 

 

 

 

 

 

 

22,388,060

 

 

 

 

5,711,805

Options exercisable at $0.45 each on or before 30 June 2018

 

Options exercisable at $0.50 each on or before 31 March 2020

 

Options exercisable at $0.60 each on or before 31 March 2020

 

Options exercisable at $0.80 each on or before 31 March 2020

 

Performance share rights subject to various performance conditions to be satisfied prior to relevant milestones or expiry dates between 31 December 2018 and 31 December 2020

 

Convertible loan note with a principal amount of $15,000,000, exchangeable into 44,776,120 ordinary shares at a conversion price of $0.335 per share with no expiry date ("Loan Note 1").

 

Agreement to issue unlisted options exercisable at $0.60 each expiring 3 years after conversion of Loan Note 1.

 

Convertible loan note with a principal amount of $2,627,430, convertible into 5,711,805 ordinary shares at a conversion price of $0.46 per share with no expiry date ("Loan Note 2")

 

 

 

10

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

Not applicable

      

 

Part 2 ‑ Pro rata issue

 

11

Is security holder approval required?

 

Not applicable

 

 

 

12

Is the issue renounceable or non-renounceable?

Not applicable

 

 

 

13

Ratio in which the +securities will be offered

Not applicable

 

 

 

14

+Class of +securities to which the offer relates

Not applicable

 

 

 

15

+Record date to determine entitlements

Not applicable

 

 

 

16

Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?

Not applicable

 

 

 

17

Policy for deciding entitlements in relation to fractions

 

Not applicable

 

 

 

18

Names of countries in which the entity has security holders who will not be sent new offer documents

Note: Security holders must be told how their entitlements are to be dealt with.

Cross reference: rule 7.7.

Not applicable

 

 

 

19

Closing date for receipt of acceptances or renunciations

Not applicable

 

 

 

 

 

 

 

 

20

Names of any underwriters

 

 

Not applicable

 

 

 

21

Amount of any underwriting fee or commission

Not applicable

 

 

 

22

Names of any brokers to the issue

 

 

Not applicable

 

 

 

23

Fee or commission payable to the broker to the issue

Not applicable

 

 

 

24

Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders

Not applicable

 

 

 

25

If the issue is contingent on security holders' approval, the date of the meeting

Not applicable

 

 

 

26

Date entitlement and acceptance form and offer documents will be sent to persons entitled

Not applicable

 

 

 

27

If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders

Not applicable

 

 

 

 

 

28

Date rights trading will begin (if applicable)

Not applicable

 

 

 

29

Date rights trading will end (if applicable)

 

 

Not applicable

 

 

 

30

How do security holders sell their entitlements in full through a broker?

Not applicable

 

 

 

31

How do security holders sell part of their entitlements through a broker and accept for the balance?

Not applicable

 

 

 

32

How do security holders dispose of their entitlements (except by sale through a broker)?

Not applicable

 

 

 

33

+Issue date

 

 

Not applicable

 

Part 3 ‑ Quotation of securities

You need only complete this section if you are applying for quotation of securities

 

34

Type of +securities

(tick one)

 

(a)

 

+Securities described in Part 1

 

 

 

 

(b)

 

All other +securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

 

Entities that have ticked box 34(a)

 Additional securities forming a new class of securities

 

Tick to indicate you are providing the information or documents

 

 

 

35

 

If the +securities are +equity securities, the names of the 20 largest holders of the additional +securities, and the number and percentage of additional +securities held by those holders

 

 

 

36

 

If the +securities are +equity securities, a distribution schedule of the additional +securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

 

 

 

37

 

A copy of any trust deed for the additional +securities

 

Entities that have ticked box 34(b)

 

38

Number of +securities for which +quotation is sought

 

Not applicable

 

 

 

 

 

39

+Class of +securities for which quotation is sought

 

Not applicable

 

 

 

 

 

40

Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

 

If the additional +securities do not rank equally, please state:

· the date from which they do

· the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment

· the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

Not applicable

 

 

 

 

 

41

Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

 

(if issued upon conversion of another +security, clearly identify that other +security)

 

Not applicable

 

 

 

 

 

 

 

Number

+Class

42

Number and +class of all +securities quoted on ASX (including the +securities in clause 38)

 

 

 

Not applicable

 

Not applicable

     

 

Quotation agreement

 

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

 

2 We warrant the following to ASX.

 

· The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.

 

· There is no reason why those +securities should not be granted +quotation.

 

· An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

 

· Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.

 

· If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

 

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

 

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

 

[signed electronically without signature]

Sign here: ............................................................ Date: 7 February 2018

(Director/Company secretary)

 

 

Print name: Dylan Browne

 

== == == == ==

Appendix 3B - Annexure 1

 

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

 

Part 1

 

Rule 7.1 - Issues exceeding 15% of capital

Step 1: Calculate "A", the base figure from which the placement capacity is calculated

Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue

151,858,969

Add the following:

• Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2

• Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval

• Number of partly paid +ordinary securities that became fully paid in that 12 month period

Note:

• Include only ordinary securities here - other classes of equity securities cannot be added

• Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

• It may be useful to set out issues of securities on different dates as separate line items

 

11,500,000 Ordinary shares (3 April 2017)

570,000 ordinary shares (9 June 2017)

2,110,000 ordinary shares (16 June 2017)

1,340,000 ordinary shares (6 July 2017)

Subtract the number of fully paid +ordinary securities cancelled during that 12 month period

Nil

"A"

167,378,969

 

Step 2: Calculate 15% of "A"

"B"

0.15

[Note: this value cannot be changed]

Multiply "A" by 0.15

25,106,845

Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used

Insert number of +equity securities issued or agreed to be issued in that 12 month period not counting those issued:

• Under an exception in rule 7.2

• Under rule 7.1A

• With security holder approval under rule 7.1 or rule 7.4

Note:

• This applies to equity securities, unless specifically excluded - not just ordinary securities

• Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed

• It may be useful to set out issues of securities on different dates as separate line items

 

 

120,000 Ordinary shares (17 Mar 2017)

500,000 Incentive options (15 Sep 2017)

 

"C"

620,000

Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1

"A" x 0.15

Note: number must be same as shown in Step 2

25,106,845

Subtract "C"

Note: number must be same as shown in Step 3

620,000

Total ["A" x 0.15] - "C"

24,486,845

[Note: this is the remaining placement capacity under rule 7.1]

 

Part 2

 

Rule 7.1A - Additional placement capacity for eligible entities

Step 1: Calculate "A", the base figure from which the placement capacity is calculated

"A"

Note: number must be same as shown in Step 1 of Part 1

Not applicable

Step 2: Calculate 10% of "A"

"D"

0.10

Note: this value cannot be changed

Multiply "A" by 0.10

Not applicable

Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used

Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A

Notes:

• This applies to equity securities - not just ordinary securities

• Include here - if applicable - the securities the subject of the Appendix 3B to which this form is annexed

• Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained

• It may be useful to set out issues of securities on different dates as separate line items

Not applicable

"E"

Not applicable

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A

"A" x 0.10

Note: number must be same as shown in Step 2

Not applicable

Subtract "E"

Note: number must be same as shown in Step 3

Not applicable

Total ["A" x 0.10] - "E"

Not applicable

Note: this is the remaining placement capacity under rule 7.1A

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEEALAXEAPPEEF
Date   Source Headline
15th Dec 20217:00 amRNSChange of Company Name
6th Dec 20217:00 amRNSChange of Director’s Interest Notice x3
3rd Dec 20217:00 amRNSNotice of Shortfall for Entitlements Issue
25th Nov 20217:00 amRNSCompany Presentation
24th Nov 20217:00 amRNSResult of AGM
10th Nov 20217:00 amRNSDispatch Of Documents for Entitlements Issue
2nd Nov 20217:00 amRNSEntitlements Offer Document
29th Oct 20217:00 amRNSSeptember 2021 Quarterly Report
28th Oct 20217:00 amRNSResults in Poland & Changes to Entitlements Price
20th Oct 20217:00 amRNSNotice of AGM
13th Oct 20217:52 amRNSCompany Presentation
8th Oct 20217:00 amRNSInitial and Final Director's Interest Notices
8th Oct 20217:00 amRNSIssue of ordinary shares and performance rights
6th Oct 20217:00 amRNSPDZ Acquires Interest in Greenland Copper Province
29th Sep 20217:55 amRNSAnnual report to shareholders
4th Aug 20217:55 amRNSFinal Director’s Interest Notice
30th Jul 20217:00 amRNSJune 2021 Quarterly Report
9th Jun 20217:00 amRNSPrairie Files £806 million Statement of Claim
4th Jun 20217:55 amRNSChange of Director’s Interest Notice
30th Apr 20217:00 amRNSMarch 2021 Quarterly Report
31st Mar 20217:13 amRNSPolish 31 December 2020 Interim Financial Report
11th Mar 20217:00 amRNSHalf-year Report
5th Feb 20217:55 amRNSResignation of Alternate Director
29th Jan 20217:00 amRNSDecember 2020 Quarterly Report
20th Jan 20217:55 amRNSResult of AGM
6th Jan 20217:00 amRNSResponse to ASX Price & Volume Query
5th Jan 20219:06 amRNSSecond Price Monitoring Extn
5th Jan 20219:00 amRNSPrice Monitoring Extension
4th Jan 20217:55 amRNSChange of Director's Interest Notice
4th Jan 20217:50 amRNSEU Home Member State
30th Dec 20207:55 amRNSReport on Payments to Govts
10th Dec 20207:55 amRNSNotice of AGM
20th Nov 20207:55 amRNSDate of Annual General Meeting
4th Nov 20207:55 amRNSChange in substantial holding
30th Oct 20207:55 amRNSSeptember 2020 Quarterly Rpeort
2nd Oct 20207:55 amRNSChange of Director's Interest Notice
30th Sep 20207:55 amRNSAnnual Report to shareholders
17th Sep 20207:55 amRNSShare Purchase Plan Results
9th Sep 20207:00 amRNSDamages Claim Against Poland Formally Commences
27th Aug 202010:04 amRNSSPP - Further Extension to Closing Date
11th Aug 20207:51 amRNSSPP - Closing Date Extended
31st Jul 20207:00 amRNSJune 2020 Quarterly Report
28th Jul 202011:40 amRNSShare Purchase Plan - Information Memorandum
24th Jul 20207:35 amRNSShare Purchase Plan - For Polish Residents
21st Jul 20207:07 amRNSShare Purchase Plan
30th Jun 20202:05 pmRNSSecond Price Monitoring Extn
30th Jun 20202:00 pmRNSPrice Monitoring Extension
30th Jun 20207:30 amRNSPrairie Secures A$18m Litigation Funding
30th Apr 20207:00 amRNSMarch 2020 Quarterly Report
10th Mar 20207:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.